[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-418094-105":59,"doc-detail-418094-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","safety-and-efficacy-of-combining-midostaurin-and-gemtuzumab-ozogamicin-with-induction-chemotherapy-in-flt3-mutated-aml","Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML","","Evaluates the safety and efficacy of combining midostaurin with gemtuzumab ozogamicin and intensive induction chemotherapy (daunorubicin plus cytarabine) for younger patients with newly diagnosed FLT3-mutated AML in the UK NCRI AML19 trial. In 195 randomized patients, 77 received midostaurin for 2 weeks after each chemotherapy course with 1-year maintenance unless transplant. The study reports high overall response, 0% day-60 mortality, no added toxicity versus historical contemporaneous regimens, improved MRD clearance, and sets up further randomized evaluation of the DAGO2 regimen.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/safety-and-efficacy-of-combining-midostaurin-and-gemtuzumab-ozogamicin-with-induction-chemotherapy-in-flt3-mutated-aml/418094/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/safety-and-efficacy-of-combining-midostaurin-and-gemtuzumab-ozogamicin-with-induction-chemotherapy-in-flt3-mutated-aml/418094.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment combination is evaluated in the AML19 trial?","Question",{"text":112,"@type":113},"The trial evaluates daunorubicin plus cytarabine with gemtuzumab ozogamicin and midostaurin (DAGO+m). Patients received either 1 or 2 doses of GO (DAGO1 and DAGO2).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was midostaurin administered for patients with FLT3 mutation?",{"text":117,"@type":113},"Midostaurin was given for 2 weeks after each chemotherapy course, followed by 1-year maintenance unless the patient received a transplant.",{"name":119,"@type":110,"acceptedAnswer":120},"What safety and early outcome results are reported?",{"text":121,"@type":113},"Day 60 mortality was 0%, and toxicity was not increased compared with contemporaneous patients treated with DAGO1 and DAGO2 without midostaurin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},418094,1790741603,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","REGULAR ARTICLE  \nSafety and efficacy of combining midostaurin and gemtuzumabozogamicin with induction chemotherapy in FLT3-mutated AML  \nNigel Russell, 1 Jad Othman,2, 3 Oliver Cumming,4 Abin Thomas,4 Aditya Tedjaseputra,1, 2 Nicola Potter,2 Jelena Jovanovic,2 Amanda Gilkes,5 Leona Batten,4 Joanna Canham,4 Emily Hinson,4 Manohursingh Runglall,2 Phoebe Aucken,2 Panos Kottaridis,6 Jamie Cavenagh,7 Claire Arnold,8 Sylvie Freeman,9 Mike Dennis, 10 Steven Knapper,5 and Richard Dillon 1, 2  \n1 Department of Clinical Haematology, Guy’s and St Thomas’ Hospitals NHS Trust, London, United Kingdom; 2 Department of Medical and Molecular Genetics, King’s College, London, United Kingdom; 3 Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; 4 Centre for Trials Research and 5 Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom; 6 Department of Haematology, University College London Hospitals NHS Trust, London, United Kingdom; 7 Department of Haematology, Bart’s and the London Hospitals NHS Trust, London, United Kingdom; 8 Department of Haematology, Belfast City Hospital, Belfast, United Kingdom; 9 Clinical Immunology Service, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom; and 10 Department of Haematology, The Christie Hospital NHS Trust, Manchester, United Kingdom  \nKey Points  \n• Midostaurin can be safely combined with GO and intensive induction chemotherapy in FLT3mut AML.  \n• The addition of midostaurin to DAGO increased the clearance of molecular MRD assessed by RTqPCR (for NPM1 mutation) and NGS (for FLT3-ITD) .  \nDespite the use of FMS-like tyrosine kinase 3 (FLT3) inhibitors, outcomes for patients with FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) remain suboptimal because of high rates of relapse. We evaluated the safety and efficacy of the combination of daunorubicin, cytarabine (DA), gemtuzumab ozogamicin (GO), and midostaurin (DAGO+m) for younger patients with newly diagnosed FLT3mut AML in the UK National Cancer Research Institute AML19 trial. A total of 195 patients were randomized to receive DA with either 1 or 2 doses of GO (DAGO1 and DAGO2) . Overall, 77 had an FLT3 mutation and received midostaurin for 2 weeks after each chemotherapy course and then as maintenance for 1 year unless they received a transplant. A total of 39 patients received DAGO1+m and 38 DAGO2+m. Their median age was 51 years (range, 20-74), and 16 (20%) were aged >60 years. The overall response rate was 91% . Day 60 mortality was 0%, with no increase in toxicity compared with patients treated contemporaneously with DAGO1 and DAGO2 without midostaurin. Two-year overall survival was 77% . Two-year event-free survival and cumulative incidence of relapse were 62% and 31%, respectively. Measurable residual disease (MRD) clearance was enhanced compared with patients with FLT3mut AML treated with DAGO without midostaurin. Overall, 81% of evaluable patients were NPM1 MRD negative in the peripheral blood after course 2 (76% with DAGO1+m, and 86% with DAGO2 +m), 79% were MRD negative in the bone marrow by FLT3-ITD next-generation sequencing, and all patients had FLT3-MRD levels \u003C0.01% . DAGO+m appears safe and effective. DAGO2+m will now be evaluated in a randomized study. This trial was registered at [www.isrctn.com](www.isrctn.com) as \\#ISRCTN78449203 .  \nSubmitted 23 May 2025; accepted 3 September 2025; prepublished online on Blood Advances First Edition 3 October 2025. [https://doi.org/10.1182/](https://doi.org/10.1182/)[ ](https://doi.org/10.1182/)[bloodadvances.2025017244](bloodadvances.2025017244.)[.](bloodadvances.2025017244.)  \nAccess to deidentified data and supporting information can be requested by qualified researchers who engage in rigorous, scientific research. Data may be provided after review and approval of a research proposal, statistical analysis plan, and execution of  \na data sharing agreement. Requests should be directed to the trial s","cbCaidGhfmBpvTtI","https://ap.wps.com/l/cbCaidGhfmBpvTtI","pdf",398086,12,"English","# Key Points\n# Introduction\n## Rationale for combining FLT3 inhibitors with intensive chemotherapy\n## Role of gemtuzumab ozogamicin (GO) in AML\n## Study aims in the AML19 trial","[{\"question\":\"What treatment combination is evaluated in the AML19 trial?\",\"answer\":\"The trial evaluates daunorubicin plus cytarabine with gemtuzumab ozogamicin and midostaurin (DAGO+m). Patients received either 1 or 2 doses of GO (DAGO1 and DAGO2).\"},{\"question\":\"How was midostaurin administered for patients with FLT3 mutation?\",\"answer\":\"Midostaurin was given for 2 weeks after each chemotherapy course, followed by 1-year maintenance unless the patient received a transplant.\"},{\"question\":\"What safety and early outcome results are reported?\",\"answer\":\"Day 60 mortality was 0%, and toxicity was not increased compared with contemporaneous patients treated with DAGO1 and DAGO2 without midostaurin.\"}]","Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML | PDF",1790611940]